EPISODE · Mar 26, 2026 · 22 MIN
Can Early Genetic Testing Change ATTR-CM Outcomes?
from Medscape InDiscussion: ATTR-CM · host Dr Kevin M. Alexander, Dr Joban Vaishnav
Drs Kevin Alexander and Joban Vaishnav explore when and how to use genetic testing in ATTR-CM, why distinguishing hereditary from wild-type disease matters, and what this means for patients' families. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-attr-cm-s1-ep2-2026a10006ha. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Transthyretin-Related Amyloidosis https://emedicine.medscape.com/article/335301-overview Tafamidis Treatment for Patients With Transthyretin Amyloid Cardiomyopathy https://pubmed.ncbi.nlm.nih.gov/30145929/ Molecular Mechanisms and Emerging Therapies in Wild-Type Transthyretin Amyloid Cardiomyopathy https://pubmed.ncbi.nlm.nih.gov/38233673/ Hereditary Transthyretin Amyloidosis (ATTRv) https://pubmed.ncbi.nlm.nih.gov/39954876/ 99mTc Bone-Avid Tracer Cardiac Scintigraphy: Role in Noninvasive Diagnosis of Transthyretin Cardiac Amyloidosis https://pubmed.ncbi.nlm.nih.gov/36537896/ Utility of Genetic Testing in Patients With Transthyretin Amyloid Cardiomyopathy: A Brief Review https://pubmed.ncbi.nlm.nih.gov/38275387/ Clinical Comparison of V122I Genotypic Variant of Transthyretin Amyloid Cardiomyopathy With Wild-Type and Other Hereditary Variants: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/33768376/ V122I TTR Cardiac Amyloidosis in Patients of African Descent: Recognizing a Missed Disease or the Dog That Didn't Bark?https://pubmed.ncbi.nlm.nih.gov/27618856/ Genetic and Clinical Features of Hereditary Transthyretin Amyloidosis: A Decade of Experience at a Japanese Referral Center https://pubmed.ncbi.nlm.nih.gov/40898332/ Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis https://pubmed.ncbi.nlm.nih.gov/41095902/ Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant https://clinicaltrials.gov/study/NCT06563895 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Embed this episode
NOW PLAYING
Can Early Genetic Testing Change ATTR-CM Outcomes?
No transcript for this episode yet
Similar Episodes
No similar episodes found.